Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amicus Therapeutics
(NQ:
FOLD
)
11.61
+0.31 (+2.74%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amicus Therapeutics
< Previous
1
2
3
4
5
Next >
Amicus Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know
April 27, 2022
Amicus Therapeutics (NASDAQ:FOLD) will host a conference call at 08:30 AM ET on May 9, 2022, to discuss Q1 2022 earnings results.
Via
Benzinga
Amicus Shares Encouraging Long-Term Data Of AT-GAA Study In Pompe Disease
March 16, 2022
Amicus Therapeutics Inc (NASDAQ: FOLD) has
Via
Benzinga
Gene Therapy Player Amicus Therapeutics Terminates SPAC Merger, Shares Fall
February 24, 2022
Amicus Therapeutics Inc (NASDAQ: FOLD) has terminated its plans to spin off its gene therapy assets, citing 'existing market conditions.' With "market...
Via
Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
February 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...
Via
Benzinga
Amicus Therapeutics Earnings Preview
February 23, 2022
Amicus Therapeutics (NASDAQ:FOLD) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 14, 2022
January 14, 2022
Upgrades According to Seaport Global, the prior rating for Lennar Corp (NYSE:
Via
Benzinga
10 Biggest Price Target Changes For Friday
January 14, 2022
Keybanc cut Robinhood Markets, Inc. (NASDAQ:HOOD...
Via
Benzinga
60 Biggest Movers From Yesterday
January 11, 2022
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ: ZNGA) rose 40.7% to settle at $8.44 after the company...
Via
Benzinga
Mid-Afternoon Market Update: Dow Tumbles 250 Points; Zynga Shares Spike Higher
January 10, 2022
Toward the end of trading Monday, the Dow traded down 0.70% to 35,978 while the NASDAQ fell 0.93% to 14,796.51. The S&P also fell, dropping, 0.72% to 4,643.29. The U.S....
Via
Benzinga
Mid-Day Market Update: Nasdaq Dips 300 Points; Apria Shares Surge
January 10, 2022
Midway through trading Monday, the Dow traded down 1.23% to 35,787.07 while the NASDAQ fell 2.07% to 14,627.21. The S&P also fell, dropping, 1.52% to 4,605.95. The U.S. has...
Via
Benzinga
45 Stocks Moving In Monday's Mid-Day Session
January 10, 2022
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares climbed 71.5% to $5.88. Zynga Inc. (NASDAQ: ZNGA) gained 45.7% to $8.74 after the company announced it will be acquired...
Via
Benzinga
Amicus Therapeutics, inc (FOLD) Q3 2021 Earnings Call Transcript
November 09, 2021
FOLD earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Benzinga's Top Ratings Upgrades, Downgrades For November 15, 2021
November 15, 2021
Upgrades For Targa Resources Corp (NYSE:
Via
Benzinga
The Week In SPAC News - Sunday, Oct. 3
October 03, 2021
In SPAC news this week, Amicus Therapeutics announced its intent to sell its gene therapy unit to ARYA Sciences Acquisition Corp IV, a SPAC sponsored by Perceptive Advisors.
Via
Talk Markets
Perceptive Advisors-Backed SPAC To Acquire Amicus's Gene Therapy Business
September 29, 2021
Amicus Therapeutics Inc (NASDAQ: FOLD) has agreed to spin off its gene therapy business to Sciences Acquisition Corp IV (NASDAQ: ARYD) and launch genetic...
Via
Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
November 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...
Via
Benzinga
Why Are Amicus Therapeutics Shares Trading Higher Today?
September 29, 2021
The FDA has accepted for review Amicus Therapeutics Inc's (NASDAQ: FOLD) Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug...
Via
Benzinga
Exposures
Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
September 30, 2021
Upgrades For Cabot Oil & Gas Corp (NYSE:COG),...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
September 29, 2021
Gainers Geovax Labs (NASDAQ:GOVX) shares increased by 23.44% to $5.16 during Wednesday's pre-market session. The market value of their outstanding shares is at $32.6...
Via
Benzinga
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
September 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Tuesday's After-Market Session
September 07, 2021
Gainers Cellectar Biosciences (NASDAQ:CLRB
Via
Benzinga
Is It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021?
August 12, 2021
One particular group of stocks is overrepresented among the exchange's biggest losers this year. That's an important detail.
Via
The Motley Fool
Amicus Therapeutics, inc (FOLD) Q2 2021 Earnings Call Transcript
August 05, 2021
FOLD earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Amicus's Fabry Disease Medicine Gets European Approval For Use In Adolescents
August 02, 2021
The European Commission has approved Amicus Therapeutics Inc (NASDAQ: FOLD) Galafold (migalastat) for use in adolescents with Fabry disease who have an amenable...
Via
Benzinga
14 Biotech Stocks To Watch Over The Next 6 Months
June 23, 2021
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ:...
Via
Benzinga
Amicus Therapeutics Insights: Return On Capital Employed
June 23, 2021
Amicus Therapeutics (NASDAQ:FOLD) reported Q1 sales of $66.40 million. Earnings fell to a loss of $52.58 million, resulting in a 18.31% decrease from last quarter. In Q4, Amicus...
Via
Benzinga
Looking Into Amicus Therapeutics's Return On Capital Employed
June 07, 2021
During Q1, Amicus Therapeutics (NASDAQ:FOLD) brought in sales totaling $66.40 million. However, earnings decreased 18.31%, resulting in a loss of $52.58 million. In Q4, Amicus...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
May 27, 2021
Gainers Cellect Biotechnology (NASDAQ:APOP
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 27, 2021
May 27, 2021
Upgrades Craig-Hallum upgraded the previous rating for NVIDIA Corp (NASDAQ:NVDA) from Hold to Buy. In the first quarter, NVIDIA showed an EPS of $3.66, compared to $1.80...
Via
Benzinga
The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing
May 26, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 25) ESSA Pharma Inc. (NASDAQ:...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.